Skip to content

A Comparative Study of Tegileridine Fumarate versus Sufentanil for Postoperative Analgesia Following Laparoscopic Total Hysterectomy: A Prospective, Randomized, Double-Blind, Controlled Clinical Trial Focusing on Quality of Recovery as the Primary Endpoint.

A Comparative Study of Tegileridine Fumarate versus Sufentanil for Postoperative Analgesia Following Laparoscopic Total Hysterectomy: A Prospective, Randomized, Double-Blind, Controlled Clinical Trial Focusing on Quality of Recovery as the Primary Endpoint.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113605
Enrollment
Unknown
Registered
2025-12-01
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological uterine diseases

Interventions

Experimental group:Postoperative analgesia: Tigillitin fumarate is prepared at 0.05mg/ml
Control group:Postoperative analgesia: Sufentanil is prepared at 5ug/ml

Sponsors

Liaocheng Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Female patients aged 40-60 years. 2. American Society of Anesthesiologists (ASA) physical status I-II. 3. Body mass index (BMI) ranging from 18 to 28 kg/m². 4. Scheduled for elective gynecological laparoscopic hysterectomy. 5. Patients provided informed consent, agreed to use a patient-controlled analgesia (PCA) pump postoperatively, were willing to accept follow-up, and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergy to the investigational drugs (Taijiliding, Sufentanil) or any of their components. 2. Severe cardiac, pulmonary, hepatic, or renal insufficiency (e.g., LVEF <50%, creatinine clearance <30 ml/min) or presence of neurological diseases. 3. Long-term use of opioid analgesics or sedative medications, or a history of drug abuse/dependence. 4. Participation in other drug clinical trials within the past 1 month. 5. Communication barriers or psychiatric disorders that prevent cooperation with pain assessment. 6. Patients with severe respiratory depression, such as oxygen saturation below 90%. 7. Acute or severe bronchial asthma patients in settings without vital sign monitoring or life resuscitation equipment. 8. Known or suspected gastrointestinal obstruction, including paralytic ileus.

Design outcomes

Primary

MeasureTime frame
The 15-item Postoperative Recovery Quality Scale (QoR-15) score at 48 hours after the operation;

Secondary

MeasureTime frame
Postoperative 24-hour (QoR-15) score;The time of the first postoperative ambulation, the time of the first defecation, and the postoperative hospital stay;The resting and movement (coughing) VAS pain scores at 2 hours, 6 hours, 24 hours, and 48 hours after the operation;The number of times the analgesic pump was pressed within 48 hours after the operation;Dosage of medication;Adverse events within 48 hours after the operation;

Countries

China

Contacts

Public ContactZhang Zhimei

Liaocheng Second People's Hospital

463654990@qq.com+86 150 9502 7798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026